AbbVie completes acquisition of Apogee Therapeutics for USD 10.9 billion - ABBV News | RalliesAbbVie completes acquisition of Apogee Therapeutics for USD 10.9 billion
A
ABBV• AbbVie completes Apogee acquisition
- AbbVie completed its acquisition of Apogee Therapeutics, paying USD 135.11 per share in cash for about USD 10.9 billion.
- Apogee shareholders were cashed out; the stock stopped trading on Nasdaq before the market opened on Sept. 3, 2026.
- Deal adds immunology pipeline assets led by IL-13 antibody zumilokibart for atopic dermatitis, with longer-acting dosing under evaluation.
- AbbVie expects a USD 0.14 hit to 2026 adjusted diluted EPS, about USD 0.46 in 2027; accretion forecast from 2032.
- 2026 adjusted diluted EPS guidance reaffirmed at USD 13.87 to USD 14.07, including the acquisition’s partial-year dilution.
SON
•
